SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis

Swedish Orphan Biovitrum AB  (OTC: BIOVF ) and Sanofi SA  (NASDAQ: SNY ) presented results  from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001) in previously treated hemophilia A patients. The study met the primary efficacy endpoint, with once-weekly efanesoctocog alfa prophylaxis providing clinically meaningful bleed protection. The median and mean annualized bleeding ... Full story available on